Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 11/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.43 |
| ▸ | REN | P00797 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4526670 | 0.92 | REN (0.43) | SLC6A4SLC6A2RENSLC6A3HTR2A | |
| SCHEMBL4536003 | 0.85 | TSHR (0.43) | RENNR1H4HTR2A | |
| SCHEMBL4524715 | 0.82 | ALDH1A1 (0.42) | SLC6A4SLC6A2RENSLC6A3HTR2A | |
| SCHEMBL1751224 | 0.81 | REN (0.45) | RENHTR2AKCNH2 | |
| SCHEMBL663586 | 0.80 | REN (0.43) | SLC6A4SLC6A2RENSLC6A3TACR1 | |
| SCHEMBL1752126 | 0.79 | REN (0.43) | RENHTR2AKCNH2TACR1 | |
| SCHEMBL1072359 | 0.78 | SLC6A4 (0.42) | SLC6A4SLC6A2RENSLC6A3HTR2A | |
| SCHEMBL4521538 | 0.78 | HSD11B1 (0.45) | SLC6A4SLC6A2RENSLC6A3NR1H4 | |
| SCHEMBL1752078 | 0.78 | REN (0.42) | SLC6A4SLC6A2RENSLC6A3NR1H4 | |
| SCHEMBL1072457 | 0.77 | REN (0.45) | SLC6A4SLC6A2RENSLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | PLE PATRICK | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036474-A1 | Quinazoline derivatives for use against cancer | AQP3, AQP1, F12 | SLC6A4 478/4885SLC6A2 533/4885REN 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.